Named Bioactive Compounds · Compound
Chlorogenic acid
Strong Evidencecompound
Hermetica Superfood Encyclopedia
Chlorogenic acid is a phenolic compound found primarily in green coffee beans that inhibits glucose-6-phosphatase and modulates lipid metabolism. Clinical trials demonstrate significant improvements in liver fat reduction and metabolic dysfunction-associated steatotic liver disease.
Chlorogenic acid (CGA) is a polyphenolic compound found abundantly in green coffee beans (Coffea arabica), tea leaves, and various fruits and vegetables. It is typically extracted using ethanol or water-based methods from green coffee beans and purified to yield standardized extracts containing up to 50% CGA.
A 2023 randomized controlled trial (n=100) demonstrated that CGA-rich Altilix® supplementation for 3 months significantly reduced hepatic steatosis by 17.7% and improved multiple metabolic parameters (PMC11205996). Meta-analysis of RCTs found green coffee bean extract with 500mg/day CGA reduced body weight, while another RCT (n=65) showed 22.5mg CGA in enriched ham reduced oxidative stress markers (PMC11013850, PMID: 37710316).
Clinical studies used 22.5-500mg CGA daily, with most metabolic benefits seen at 500mg/day from green coffee bean extract standardized to 50% CGA. For liver health, therapeutic doses of Altilix® (standardized CGA extract) were effective. Maximum safe dose appears to be 1g/day, with doses above 2g/day potentially increasing homocysteine levels. Consult a healthcare provider before starting any new supplement.
Chlorogenic acid (CGA) is a polyphenolic ester formed from caffeic acid and quinic acid (5-O-caffeoylquinic acid being the most abundant isomer). It is not a macronutrient source and provides negligible calories, protein, fat, or fiber. Key bioactive profile: • Primary compound: 5-caffeoylquinic acid (5-CQA), with related isomers including 3-CQA, 4-CQA, 3,4-diCQA, 3,5-diCQA, and 4,5-diCQA. • Typical dietary concentrations: green (unroasted) coffee beans contain 6–12% CGA by dry weight (~35–60 mg/g); brewed coffee provides ~70–350 mg CGA per 200 mL cup; roasted coffee retains ~1.5–4% due to thermal degradation. • Other dietary sources: yerba mate (~8.2 mg/g dry leaf), sunflower seeds (~2.5–3.0% dry weight), blueberries (~0.5–1.0 mg/g fresh weight), apples (~0.1–0.5 mg/g fresh weight), artichokes (~1–2% dry weight), eggplant peel, potatoes, and plums. • Molecular weight: 354.31 g/mol; water-soluble phenolic acid conjugate. • Bioavailability notes: Only ~33% of ingested CGA is absorbed intact in the small intestine; the majority (~67%) reaches the colon where gut microbiota hydrolyze it into caffeic acid and quinic acid, which are then absorbed. Peak plasma concentrations occur at ~1–2 hours (intact CGA) and ~4–8 hours (microbial metabolites including dihydrocaffeic acid, ferulic acid, hippuric acid, and 3-(3-hydroxyphenyl)propionic acid). Plasma half-life of intact CGA is approximately 1–2 hours. Extensive phase II metabolism yields glucuronide, sulfate, and methylated conjugates. Bioavailability is enhanced when consumed with a food matrix (e.g., coffee) and may be reduced by binding to dietary proteins. • Supplemental doses in clinical research: typically 200–1000 mg/day, most commonly standardized to ≥45–50% CGA from green coffee bean extract (GCE). • Contains no significant vitamins or minerals intrinsically; however, coffee as a delivery matrix contributes potassium (~116 mg/cup), magnesium (~7 mg/cup), niacin (~0.7 mg/cup), and trace manganese and riboflavin. • Antioxidant capacity: ORAC value of pure CGA is approximately 12,000–15,000 µmol TE/g, making it one of the more potent dietary phenolic antioxidants. • Key functional groups responsible for bioactivity: catechol moiety (ortho-dihydroxyl group on the caffeic acid portion) drives radical scavenging, metal chelation, and enzyme inhibition (notably α-glucosidase IC50 ~0.5–2.0 mM and pancreatic lipase inhibition).
Chlorogenic acid inhibits glucose-6-phosphatase in the liver, reducing hepatic glucose production and improving insulin sensitivity. It modulates AMPK (adenosine monophosphate-activated protein kinase) pathways, enhancing fatty acid oxidation and reducing lipogenesis. The compound also influences peroxisome proliferator-activated receptor alpha (PPARα) expression, promoting metabolic homeostasis.
A randomized controlled trial demonstrated chlorogenic acid supplementation reduced hepatic steatosis by 17.7% in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Meta-analyses of weight loss studies show moderate evidence for body weight reduction, though effect sizes vary considerably between trials. Most studies utilize dosages between 200-400mg daily, with treatment durations ranging from 8-12 weeks. The evidence for liver benefits is stronger than weight loss effects, with larger sample sizes needed for metabolic outcomes.
Chlorogenic acid is generally well-tolerated with mild side effects including occasional digestive upset and headaches. It may enhance the hypoglycemic effects of diabetes medications, requiring blood glucose monitoring in diabetic patients. The compound can increase homocysteine levels in some individuals, potentially concerning for cardiovascular risk. Safety during pregnancy and lactation has not been established, and use should be avoided in these populations.
